Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Metagenomi Therapeutics, Inc. (MGX) had Return on Equity of -16.74% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.25M |
|
$-23.06M |
|
-- |
|
$1.25M |
|
$25.84M |
|
$-24.59M |
|
$1.54M |
|
$-23.05M |
|
$-23.05M |
|
$-23.06M |
|
$-23.06M |
|
$-23.06M |
|
$-23.06M |
|
$-24.59M |
|
$-23.67M |
|
37.58M |
|
37.58M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$144.56M |
|
$11.16M |
|
$52.40M |
|
$196.95M |
|
$22.50M |
|
-- |
|
$36.67M |
|
$59.17M |
|
$137.78M |
|
$137.78M |
|
$137.78M |
|
37.65M |
|
| Cash Flow Statement Financials | |
$-21.18M |
|
$3.99M |
|
$-0.03M |
|
$46.91M |
|
$29.70M |
|
$-17.22M |
|
$2.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.43 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1970.11% |
|
-1970.11% |
|
-- |
|
-1846.88% |
|
-1847.68% |
|
$-21.20M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-16.74% |
-16.74% |
|
-11.71% |
|
-16.74% |
|
$3.66 |
|
$-0.56 |
|
$-0.56 |
|